Multiple sclerosis Archives

News and Trends 1 Jun 2023

Sanofi drug reduces disease activity in relapsing MS

New data, being presented in a late-breaking session at the 2023 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, demonstrate that frexalimab, Sanofi’s novel second-generation investigational anti-CD40L antibody, with a…

June 1, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 7 Dec 2022

Neuraxpharm’s expansion into the Netherlands takes it from two to 20 countries in six years

Neuraxpharm Group, a European pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, has announced the establishment of Neuraxpharm Netherlands, increasing its presences from two to 20…

December 7, 2022 - 3 minutesmins - By Liza Laws

News and Trends 28 Jul 2022

First of a kind multiple sclerosis biosimilar natalizumab accepted by US Food and Drug Association

Sandoz, a global pharmaceutical company working in generic and biosimilar medicines, announced this week that the US Food and Drug Administration (FDA) has accepted its biologics application (BLA) for treatment…

July 28, 2022 - 3 minutesmins - By Liza Laws

geneuro multiple sclerosis neuron viral dna

News and Trends 18 Jul 2022

First-ever Marketing Authorization Application for biosimilar targeting MS filed

An international biotech, with headquarters in Amsterdam, has announced that the European Medicines Agency (EMA) has accepted the first-ever Marketing Authorization Application (MAA) for its biosimilar product. Polpharma Biologics, which…

July 18, 2022 - 3 minutesmins - By Liza Laws

multiple sclerosis novartis roche ema approval

News and Trends 27 Apr 2021

EMA Approvals for Multiple Sclerosis Highlight Treatment Shortfalls

While the EU saw rapid-fire approvals in the multiple sclerosis space last month, the innovations centered mostly on improving existing approaches. Which areas of multiple sclerosis treatment need more options?…

April 27, 2021 - 6 minutesmins - By Jonathan Smith

multiple sclerosis neuron sheath medday Pharma

News and Trends 11 Mar 2020

Phase III Fail for MedDay’s Multiple Sclerosis Treatment

A drug developed by the French company MedDay Pharmaceuticals has failed to treat progressive forms of multiple sclerosis in a phase III trial. The 642 patients recruited into the trial…

March 11, 2020 - 2 minutesmins - By Jonathan Smith

News and Trends 17 Sep 2019

European Biotechs Showcase Multiple Sclerosis Treatments in Stockholm

Genmab, GeNeuro and other companies presented their latest data on next-generation treatments for multiple sclerosis at a conference in Stockholm. The European Committee for Treatment and Research in Multiple Sclerosis…

September 17, 2019 - 4 minutesmins - By Jonathan Smith

News and Trends 12 Mar 2019

Blocking Hidden Viral Protein Shows Promise for Treating Multiple Sclerosis

An antibody that blocks the action of a hidden viral protein encoded by our genome shows encouraging signs of slowing down the progression of multiple sclerosis, according to the Swiss…

March 12, 2019 - 3 minutesmins - By Jonathan Smith

Altheia Science gene therapy autoimmune disease

News and Trends 19 Dec 2018

Italian Biotech Raises Big Series A for ‘Gene Therapy 2.0’

Altheia Science, based in Milan, has raised €17M to fund the development of gene therapies for autoimmune diseases with the remarkable potential to be curative. “The success of our fundraising…

December 19, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

More News! 18 May 2018

New Treatment for Rare Neurologic Eye Disease on Horizon from Spanish Biotech

Spanish biotech Bionure has started an early stage trial of a new drug to treat rare neurologic eye diseases, which also shows promise for treatment of multiple sclerosis and other…

May 18, 2018 - 2 minutesmins - By Helen Albert

More News! 26 Mar 2018

Attacking an Ancient Virus Slows Multiple Sclerosis in Phase II

GeNeuro has released Phase IIb data showing that its antibody can reduce brain damage in patients with multiple sclerosis by going after an unusual target: a virus that has been…

March 26, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

santhera multiple sclerosis trial idebenone

News and Trends 5 Mar 2018

Swiss Company Hits Another Slump with a Failed Multiple Sclerosis Trial

Just months after the EMA rejected its therapy for Duchenne muscular dystrophy, Swiss company Santhera reports negative data for its multiple sclerosis drug. Santhera Pharmaceuticals has reported this morning that…

March 5, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 4 Jan 2018

Belgian Biotech Hits ‘Fast Forward’ on Multiple Sclerosis Therapies

Rewind Therapeutics has received a boost in the development of its multiple sclerosis therapies, raising a €15.2M Series A fundraising round. Rewind Therapeutics is a young Belgian biotech, which was co-founded…

January 4, 2018 - 2 minutesmins - By Alex Dale

topas therapeutics timm jessen interview

Interview 15 Nov 2017

Therapeutic Nanoparticle Companies Are Rare: Meet the CEO of One of Them

In our last BIO Europe interview, I caught up with CEO Timm Jessen of Topas Therapeutics to hear about the company's nanoparticles. Founded in 2013 as a spinout from Evotec,…

November 15, 2017 - 4 minutesmins - By Evelyn Warner

News and Trends 2 Nov 2017

German Biotech Pockets €18M in its Series A to Propel Autoimmune Disease Candidate Forward

Topas Therapeutics received an extra €4M from Boehringer Ingelheim Venture Fund to help its autoimmune disease candidates accelerated through trials. Hamburg-based Topas Therapeutics, a spin-off from Evotec, develops products for autoimmune diseases with high medical…

November 2, 2017 - 2 minutesmins - By Alex Dale

More News! 1 Nov 2017

Swiss Biotech & French Pharma Reverse Damage in Multiple Sclerosis

A candidate multiple sclerosis treatment from GeNeuro and its partner Servier showed some remyelination in a post hoc analysis of Phase IIb data. GeNeuro's stock rose by 30% on Monday following an…

November 1, 2017 - 2 minutesmins - By Evelyn Warner

News and Trends 1 Nov 2017

Belgian Biotech Launches IPO, Readying Itself to Fight Multiple Sclerosis

Apitope develops highly specific peptide therapeutics for multiple sclerosis and other autoimmune diseases, and will now launch an IPO on Brussels Euronext. Apitope hopes to treat a number of autoimmune…

November 1, 2017 - 2 minutesmins - By Alex Dale

News and Trends 19 Oct 2017

Austrian Researchers Identify Target for Treatment of Multiple Sclerosis

Multiple sclerosis is the most common disease of the CNS in young adults. Researchers may have stumbled across a new approach for its treatment. Researchers at the Medical University of…

October 19, 2017 - 3 minutesmins - By Alex Dale

bc platforms biogen microsoft multiple sclerosis

News and Trends 16 Oct 2017

Swiss Genomics Firm, Biogen and Microsoft Team Up to Treat Multiple Sclerosis

BC Platforms and Microsoft will be working with Biogen and the Accelerated Cure Project to study the genetics of multiple sclerosis and accelerate research. The Swiss firm BC Platforms has…

October 16, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 8 May 2017

Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis

Teva and Active Biotech have failed Phase III with their Multiple Sclerosis drug laquinimod to treat the relapsing-remitting form of the disease. Teva and Active Biotech have faced another setback…

May 8, 2017 - 2 minutesmins - By Melanie De Almeida

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

The Biotech Perspective 2023

View all companies A-Z

Find new scientific partnerships. Create a free IN-PART account

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inova, the leading platform for biopharma partnering